Probiotic-based therapy for body weight control, energy homeostasis, and TIIDM: Probiotic Clostridium butyricum MIYAIRI 588 (CBM588)  increases REV-ERB and its downstream target genes, inhibits lipid accumulation, improves dyslipidemia and insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up-regulation of its target gene, 5/February/2019, 10.17 pm

Ribonucleic acid-based therapy for cardiac hypertrophy and fibrosis: lncRNA PCGEM  decreases MiR-29 expression, activates Wnt- signaling and its components GSK3B, ICAT/CTNNBIP1, HBP1, and GLIS2, attenuates pathologic hypertrophy, inhibits fibrosis of the heart tissue, and improves cardiac function via upregulation of its target gene, 5/January/2019, 10.06 pm
February 5, 2019
Ribonucleic acid-based therapy for TIIDM and obesity-associated metabolic deficits: LncRNA  H19 increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM, via down-regulation of its target gene, 5/February/2019, 10.33 pm
February 5, 2019
Show all

Introduction: What they say

A study from the Department of Molecular Therapeutics, The Scripps Research Institute, Jupiter, Florida 33458, USA shows that “Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists.” This research paper was published, in the 29 March 2012 issue of the journal “Nature” [One of the best research journals in Science with an I.F of 43 plus], by Prof.Burris TP, Solt LA and others.


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Probiotic-based therapy for body weight control, energy homeostasis, and TIIDM: Probiotic Clostridium butyricum MIYAIRI 588 (CBM588)  increases REV-ERB and its downstream target genes, inhibits lipid accumulation, improves dyslipidemia and insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up-regulation of its target gene


From significance of the study to public health relevance:

Given that: (1) more than half a billion adults are obese worldwide ; (2) obesity is more prevalent in western countries than in asian countries; (3) obesity results in deregulated blood pressure, cholesterol, triglycerides and insulin sensitivity; and the risks of coronary heart disease, ischemic stroke and TII diabetes mellitus(TIIDM) increase ; (4) more than 422 million people worldwide are affected by Diabetes mellitus (DM); (5) Diabetes is going to be one of the top 10 causes of death by 2030; (6) the life-long painful injection/drug treatment is required to treat DM; and  (7) the global economic cost spent for diabetes treatment in 2014 was little more than 600 billion US dollars, there is an urgent need to find: (i) a way to induce regeneration of adult ß-cells that were lost in DM; (ii) a cheaper alternative to the existing expensive weight-loss drugs; (iii) a side-effect-free natural product-based drug; and (iv) a way to cure, not just treat, obesity-associated diseases, including diabetes.


What is known?

Prof.Burris’s research team has recently shown that administration of REV-ERB ligands:(1) regulates circadian behavior and the circadian pattern of core clock gene;(2) alters the circadian pattern of expression of metabolic genes in liver, skeletal muscle, and adipose tissue; (3) increases energy expenditure; (4) inhibits lipid accumulation; (4) decreases obesity; (5) improves dyslipidemia; and (6) reduces hyperglycaemia, suggesting that increasing the expression of REV-ERB may promote weight loss, augment insulin sensitivity, improve dyslipidemia and alleviate Obesity-associated TIIDM.


From Research findings to Therapeutic opportunity:

This study suggests, for the first time, a probiotic-based therapy for Weight loss and Obesity-associated TIIDM.  Probiotic Clostridium butyricum MIYAIRI 588 (CBM588), by increasing the expression of its target gene, it may increase the expression of REV-ERB. Thereby, it may: (1) normalize circadian pattern of metabolic genes; (2) augment energy expenditure; (3) inhibit lipid accumulation; (4) promote weight loss; (5) ameliorate dyslipidemia; and (6) inhibit hyperglycemia (Fig.1).

Figure 1. Mechanistic insights into how Probiotic Clostridium butyricum MIYAIRI 588 (CBM588) attenuates metabolic disease and obesity-associated TIIDM.  Clostridium butyricum MIYAIRI 588 (CBM588), by up-regulating the expression of REV-ERB, it may attenuate metabolic disease.

Figure 2. Probiotic Clostridium butyricum MIYAIRI 588 (CBM588) promotes weight loss and attenuates metabolic disease, through induction of Rev-ERB

Figure 2. Probiotic Clostridium butyricum MIYAIRI 588 (CBM588) may attenuate metabolic disease through induction of Rev-ERB

Thus,  Probiotic Clostridium butyricum MIYAIRI 588 (CBM588) may be used:(i) as a weight-loss medication; (ii) to treat Obesity-associated TIIDM; (iii) to treat sleep disorders (Figs. 2 & 3).


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does Probiotic Clostridium butyricum MIYAIRI 588 (CBM588) increase the expression of REV-ERB?

Amount: $500#

# Research cooperation

For purchase and payment details, you may reach us at info@genomediscovery.org


References:

Web: http://genomediscovery.org or http://newbioideas.com

Citation: Boominathan, L., Probiotic-based therapy for body weight control, energy homeostasis, and TIIDM: Probiotic Clostridium butyricum MIYAIRI 588 (CBM588)  increases REV-ERB and its downstream target genes, inhibits lipid accumulation, improves dyslipidemia and insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up-regulation of its target gene, 5/February/2019, 10.17 pm, Genome-2-BioMedicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite, drop us a line at info@genomediscovery.org

 

 

 

Comments are closed.